# US 2004/0019110 A1 · Lipoxin analogs and method for the treatment of periodontal disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019110 A1
- Document ID: US20040019110A1
- Status: Published application
- Kind: A1
- Application number: 10/239,444
- Filed: 2002-09-20
- Published: 2004-01-29
- Earliest claimed: 2002-09-20
- Assignees: Trustees of Boston University; The Brigham and Women's Hospital, Inc.; University of Southern California
- Inventors: Thomas E. Van Dyke; Nicos A. Petasis; Charles N. Serhan
- Web page: https://patentgrep.com/patent/US20040019110A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/365: Lactones
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 69/732: of unsaturated hydroxy carboxylic acids
- C07C 69/736: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C07C 229/30: the carbon skeleton being acyclic and unsaturated
- C07C 235/28: the carbon skeleton being acyclic and unsaturated
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07B 2200/07: Optical isomers
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This invention provides new lipoxin analogs, compositions containing these analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation,including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the compositions containing lipoxin analogs, COX-2 inhibitors, or both.

## Claims

### Claim 1

A lipoxin analog comprising one of the following four structures:
39
wherein
R is selected from the group consisting of hydrogen and straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms;
R1, R2, R12, and R13 are independently selected from the group consisting of hydrogen;
straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms;
substituted alkyl having from 1 to 20 carbon atoms, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl;
substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and
a group Z-Y, wherein
Z is selected from the group consisting of a straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms; substituted lower alkyl, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; and substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and
Y is selected from the group consisting of hydrogen; alkyl; cycloalkyl; carboxyl; carboxamido; aryl; heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido;
R3 is selected from the group consisting of
hydrogen;
straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms; substituted alkyl having from 1 to 20 carbon atoms, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl;
substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and
a group Z-Y, wherein
Z is selected from the group consisting of a branched, cyclic, or unsaturated alkyl having from 1 to 20 carbon atoms; substituted lower alkyl, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; and substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido;
Y is selected from the group consisting of hydrogen; alkyl; cycloalkyl; carboxyl; carboxamido; aryl; heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido;
R4—R11 are independently selected from a group consisting of
hydrogen;
halo;
straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms;
substituted alkyl having from 1 to 20 carbon atoms, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl;
substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; or
R1—R13 are independently a bond that forms a carbon-carbon double bond, a carbon-carbon triple bond, or a ring with the lipoxin backbone; or
R, R1—R13 independently join in any combination to form one or more rings containing 3 to 20 carbon atoms, wherein the rings optionally contain 1 to 6 oxygen atoms, 1 to 6 nitrogen atoms, or both 1 to 6 oxygen atoms and 1 to 6 nitrogen atoms.

### Claim 2 (depends on 1)

A lipoxin analog of claim 1 selected from the group consisting of the following compounds:
40 41 42 43 44 45
wherein R is selected from the group consisting of hydrogen, methyl, and phenyl; Y is selected from the group consisting of oxygen and CH2; Ra is selected from the group consisting of methyl and CF3; Rb is selected from the group consisting of a polymeric material and an alkyl, substituted alkyl, aryl, or substituted aryl group having from 1 to 20 carbon atoms; and n is an integer from 1 to 10.

### Claim 3 (depends on 1)

A composition comprising a pharmaceutically acceptable carrier and one or more lipoxin analog as defined in claim 1.

### Claim 4 (depends on 2, 3)

The composition of claim 3 wherein the lipoxin analog is as defined in claim 2.

### Claim 5 (depends on 3)

The composition of claim 3 further comprising a COX-2 inhibitor.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the composition is in a form selected from the group consisting of solutions, suspensions, dispersions, ointments, creams, pastes, powders, toothpastes, gels, lozenges, salve, chewing gum, mouth sprays, pastilles, sachets, mouthwashes, aerosols, tablets, capsules, and floss conjugated with lipoxin analogs.

### Claim 7 (depends on 3)

The composition of claim 3 wherein the lipoxin analog is incorporated into, conjugated with, or covalently linked to a polymer or biopolymer.

### Claim 8

A method of treating or preventing an oral inflammation in a human or animal comprising topically administering to the human or animal an effective amount of a composition comprising a structural analog of lipoxin A4, lipoxin B4, 15-epi lipoxin A4, or 15-epi lipoxin B4.

### Claim 9 (depends on 8)

The method of claim 8 wherein the oral inflammation is associated with a disease selected from the group consisting of gingivitis, periodontitis, aphthous ulcers, and herpetic stomatitis.

### Claim 10 (depends on 1)

A method of treating or preventing an oral inflammation in a human or animal comprising administering to the human or animal having the oral inflammation an effective amount of a composition comprising a lipoxin analog as defined in claim 1.

### Claim 11 (depends on 2, 10)

The method of claim 10 wherein the lipoxin analog is as defined in claim 2.

### Claim 12 (depends on 10)

The method of claim 10 wherein the oral inflammation is associated with a disease selected from the group consisting of gingivitis, periodontitis, aphthous ulcers, and herpetic stomatitis.

### Claim 13 (depends on 10)

The method of claim 10 wherein the administration is topical.

### Claim 14

A method of treating or preventing an oral inflammation in a human or animal comprising administering to the human or animal having the oral inflammation an effective amount of a composition comprising a pharmaceutical carrier and a COX-2 inhibitor.

### Claim 15 (depends on 14)

The method of claim 14 wherein the oral inflammation is associated with a disease selected from the group consisting of gingivitis, periodontitis, aphthous ulcers, and herpetic stomatitis.

### Claim 16 (depends on 14)

The method of claim 14 wherein the administration is topical.

### Claim 17 (depends on 14)

The method of claim 14 wherein the COX-2 inhibitor is selected from the group consisting of celecoxib, rofecoxib, and valdecoxib.

### Claim 18

A method of treating a systemic disease in a human or animal comprising administering to the human or animal an effective amount of a composition comprising a structural analog of lipoxin A4, lipoxin B4, 15-epi lipoxin A4, or 15-epi lipoxin B4.

### Claim 19 (depends on 18)

The method of claim 18 wherein the system disease is selected from the group consisting of cardiovascular diseases, pregnancy complications, and diabetes.

### Claim 20 (depends on 18)

The method of claim 18 wherein the administration is topical or oral administration.

### Claim 21 (depends on 1)

A method of treating a systemic disease related to periodontal disease in a human or animal comprising administering to the human or animal an effective amount of a composition comprising a lipoxin analog as defined in claim 1.

### Claim 22 (depends on 21)

The method of claim 21 wherein the systemic disease is selected from the group consisting of cardiovascular diseases, pregnancy complications, and diabetes.

### Claim 23 (depends on 21)

The method of claim 21 wherein the administration is topical or oral administration.

### Claim 24 (depends on 21)

The method of claim 21 wherein the composition further comprises a COX-2 inhibitor.
